



THE LAW OFFICE OF  
STEPHEN JOSEPH LASKERO  
A California Law office  
3451 Via Montebello, Suite 192-409  
Carlsbad, CA 92009  
[stephenlaw7@ymail.com](mailto:stephenlaw7@ymail.com)  
760-452-6778

---

OTC Markets Group Inc.  
300 Vesey Street, 12th Floor,  
New York, NY 10282,  
[issuers@otcmarkets.com](mailto:issuers@otcmarkets.com)

July 25, 2022

Re: Attorney Letter for Caduceus Software Systems Corp. (CSOC) Regarding Current Public Information

Dear Sir or Madam:

The purpose of this correspondence is to inform OTC Markets and the public of the availability of adequate current public information for the “issuer” Caduceus Software Systems Corp. (CSOC) a Wyoming based holding company. This law office has been retained by the Issuer for the purpose of completing a reasoned opinion regarding the availability of current public information as that term is defined in Rule 144(c) (2) of the Securities Act of 1933 as amended. The OTC Markets Group is entitled to rely on this opinion and may publish this letter through the OTC Market Disclosure and News Service (otcmarkets.com) for the purpose of making this information available to the public.

The undersigned and sole author of this correspondence is licensed to practice law in the state of California, and in the United States District Court for the Southern District of California. The undersigned is also a United States citizen permitted to practice before the United States Securities and Exchange Commission and has not been disciplined or otherwise prohibited from that practice. The author is not currently and never has been subject to an investigation, hearing, or proceeding by the Securities and Exchange Commission, the U.S. Commodity Futures Trading Commission, the Financial Industry Regulatory Authority, or any other federal, state, or foreign entity. Moreover, the undersigned never has been and is not currently suspended or barred from practice in any foreign or domestic court of law or other tribunal or been charged in a civil or criminal matter. Finally, the undersigned does not beneficially own any of the issuer’s securities and has not been promised any stock in the future.

### **Limitations, Assumptions and Facts**

In support of this opinion, the undersigned has reviewed applicable federal laws, rules and regulations of the United States of America including specifically the Securities Act of 1933 as amended and other relevant laws deemed necessary to render this opinion. The undersigned has also reviewed the corporate records determined to be appropriate, verified or assumed the legal capacity of all persons and entities, the genuineness of all signatures, the authenticity of all documents, and the veracity of all individuals who provided information regarding this matter.

In the portion of this opinion relying upon the information and documentation contained in the OTC disclosures of the issuer, the undersigned has not made, nor will he make any independent investigation regarding the representations contained therein. However, during my review of the documentation and conversations with the issuer's representatives, I did not reach the conclusion that any of the information I received was incorrect or disingenuous. Therefore, the information relied upon is believed to be true and reliable, and the documents genuine. This opinion is based solely on the facts, limitations and assumptions described in this letter and is not intended to be expanded to any other situation not discussed herein.

In the formation of the opinions contained in this letter, the undersigned has examined the following specific documents available by publication through the OTC Disclosure and News service since the last letter written by this office published on June 8, 2021 for the period ending March 31, 2021.

<u>Publish Date</u>	<u>Title</u>	<u>Period End Date</u>
07/13/2022	<u>Annual Report - Fiscal Year Ended March 31st, 2022</u>	03/31/2022
06/30/2022	<u>Notification of Late Filing - March 31, 2022</u>	03/31/2022
02/21/2022	<u>Quarterly Report - CSOC Quarterly Report - December 31, 2021</u>	12/31/2021
02/14/2022	<u>Notification of Late Filing - Notification of Late Filing</u>	12/31/2021
11/15/2021	<u>Quarterly Report - CSOC Quarterly Report - September 30, 2021</u>	09/30/2021
08/16/2021	<u>Quarterly Report - CSOC Quarterly Report - June 30, 2021</u>	06/30/2021
06/08/2021	<u>Attorney Letter with Respect to Current Information - Attorney Letter with Respect to Current Information</u>	03/31/2021
06/07/2021	<u>Annual Report - Amendment CSOC Annual Report for the Fiscal Year ended March 31, 2020</u>	03/31/2021

05/19/2021

Annual Report - CSOC Annual Report for the Fiscal Year  
ended ended March 31, 2021

03/31/2021

The undersigned also reviewed the Pink Basic Disclosure Guidelines applicable to the fiscal year ending December 31, 2021, and fiscal quarter ending March 31, 2022.

The undersigned has met with Alex Chen, the Chief Executive Officer, financial officer, and sole Director of Caduceus Software Systems Corp via telephone conference on at least three separate occasions, and in person most recently on July 3, 2022. During these conversations, the information published by the issuer was discussed and confirmed.

The annual report for the period ending March 31, 2021, and the quarterly reports for the periods ending June 30, 2021, September 30, 2021, and September 31, 2021, as well as the annual report for the period ending March 31, 2022, were prepared by Alex Chen, CEO and CFO of the company who has adequate knowledge and understanding to file the reports as described below.

The financial statements contained in the information for the fiscal year ending March 31, 2021, and the most recent annual report for the period ending March 31, 2022, are unaudited financial statements prepared by Alex Chen, the CEO and chief financial officer of the company. He is familiar with the company's financials and has a bachelor's degree in accounting, worked for Certified Public Accounting firms and was a CPA in Australia. He also served as a CFO for an Amex traded company, and holds series 79, 7 and 63 designations. During our discussions, he confirmed that the information in the financial statements is true and correct to the best of his knowledge.

After my conversations with Mr. Chen on July 3, 2022, I received written confirmation that none of the individuals identified as owning 5% or more of the company's common stock are currently under investigation by any federal or state agency for the violation of any securities laws, and never have been charged, indicted or been found guilty of any securities law violations including legal counsel. Consequently, to the best of my knowledge, after reasonable inquiry, the above referenced information can be relied upon by OTC Markets as being true.

The undersigned confirmed the number of outstanding shares of the issuer by reviewing the information contained in the yearend financial statements, contacting the transfer agent, Securities Transfer Corp., an entity registered with the Securities and Exchange Commission, and reviewing the CSOC "Security Details" available on the OTC Disclosure and News Service, as of July 15, 2022.

**Non-Shell Status**

According to the issuer's OTC disclosures it is not now and never has been a "shell company" as defined by Rule 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934. My factual inquiries support the conclusion that the company has been an ongoing concern with more than nominal assets and operations since its inception based on its OTC disclosures and my discussions with management.

**Legal Opinion**

It is the undersigns opinion that the information provided by the issuer presents "adequate current public information" regarding the issuer and its securities that is available to the public as those terms

are defined in Rule 144(c)(2) of the Securities Act of 1933. The available information contains all of the information a broker-dealer would need to publish a quote for the securities under Rule 15c2-11 of the Securities Exchange Act of 1934, as amended. It also is consistent with OTC Markets Group's Pink Basic Disclosure Guidelines that have been published through the OTC Disclosure & News Service.

The opinions contained in this letter are limited to the federal Securities laws of the United States of America, without regard to any other state, local, or municipal laws of any jurisdiction. Nothing in this correspondence should be construed as a guarantee or a definitive opinion of fact. All opinions assume that the presented documents and statements of management are true, and the facts delineated in the documents reviewed in support of this opinion are genuine. The letter is being presented in accordance with the guidelines of the OTC Market Disclosure and New Service and OTC is hereby granted complete permission and rights to publish this letter. This correspondence applies only to law, facts and circumstances described herein and should not be relied upon by any other person or entity for any purpose. No other publication, use or reproduction of this correspondence is authorized without the specific written permission of the undersigned.

Regards,



---

Stephen Laskero  
Attorney at Law